Global Approach in Safety Testing

ICH Guidelines Explained
1 The International Conference on Harmonisation: History of Safety Guidelines .............................................................. 1
Jan Willem van der Laan and Joseph J. DeGeorge

2 EU Perspective on ICH.................................................. 13
Spiros Vamvakas

3 The Value and Benefits of the International Conference on Harmonisation (ICH) to Drug Regulatory Authorities: Advancing Harmonization for Better Public Health .................... 23
Justina A. Molzon

Yasuo Ohno

5 Toward More Scientific Relevance in Carcinogenicity Testing ....... 37
Jan Willem van der Laan, Joseph J. DeGeorge, Frank Sistare, and Jonathan Moggs

6 The Evolution, Scientific Reasoning and Use of ICH S2 Guidelines for Genotoxicity Testing of Pharmaceuticals............... 77
Lutz Müller, David Tweats, Sheila Galloway, and Makoto Hayashi

7 Toxicokinetikos: A Guidance for Assessing Systemic Exposure in Toxicology Studies, Where Are We Now; An S3A/S3B Update (1995–2011)................................................................. 119
Bruce Campbell and Bob Ings

8 Duration of Acute and Chronic Toxicity Testing in Animals (ICH S4A and S4B)....................................................... 159
Per Spindler and Herman Van Cauteren
9 Why and How Did Reproduction Toxicity Testing Make Its Early Entry into and Rapid Success in ICH? ................................................................. 175
Rolf Bass, Yasuo Ohno, and Beate Ulbrich

10 ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals.......................................................... 215
Joy Cavagnaro and Jennifer Sims

11 Safety Pharmacology: Guidelines S7A and S7B ................................................. 243
John E. Koerner and Peter K.S. Siegl

12 ICH S8: History and Perspectives................................................................. 267
Kenneth L. Hastings

13 ICH S9: Nonclinical Evaluation of Anticancer Pharmaceuticals: A Perspective from Regulators on the Development of the Guideline ............................................................. 283
John K. Leighton, Klaus Olejniczak, and Hiroshi Onodera

14 Non-clinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals: ICH M3 and M3(R2) .......... 299
Per Sjöberg and David R. Jones

Biography ........................................................................................................... 311

Index................................................................................................................... 313